Premium Monovision Versus Other Types of Monovision and Bilateral Trifocal Implantation.
NCT ID: NCT04618380
Last Updated: 2020-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2018-01-01
2020-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bilateral trifocal implantation
Bilateral implantation of trifocal diffractive intraocular lenses (Panoptix, Alcon) targeting emmetropia
bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
The following clinical indexes are evaluated:
1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance
2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and
3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).
All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.
Contrast sensitivity are evaluated with the Pelli-Robson test.
Myopic monovision
The dominant eye defocus is targeted to -0.50 diopters while the recessive one to -1.25 diopters with bilateral implantation of monofocal intraocular lenses (SN60WF, Alcon)
bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
The following clinical indexes are evaluated:
1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance
2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and
3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).
All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.
Contrast sensitivity are evaluated with the Pelli-Robson test.
Hybrid monovision
Hybrid monovision combines a monofocal intraocular (SN60WF, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one
bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
The following clinical indexes are evaluated:
1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance
2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and
3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).
All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.
Contrast sensitivity are evaluated with the Pelli-Robson test.
Premium monovision
Participants received a bifocal hybrid (refractive at the centre, diffractive at the periphery) intraocular lens (Restor +2.50 diopters, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one, targeting emmetropia in both eyes.
bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
The following clinical indexes are evaluated:
1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance
2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and
3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).
All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.
Contrast sensitivity are evaluated with the Pelli-Robson test.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
The following clinical indexes are evaluated:
1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance
2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and
3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).
All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.
Contrast sensitivity are evaluated with the Pelli-Robson test.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Reports of headaches and/or eyestrain associated with visual activities
* Positive, pathologic ocular cover test (near \& distant) and / or the Mallett's disparity test (near \& distant) and the double Maddox rod test
* Endothelial cell count less than 1900/mm2
* Glaucoma
* intraocular pressure-lowering medications
* Former incisional surgery
* Former diagnosis of corneal disease
* Former diagnosis of fundus disease
* Diabetes
* Autoimmune diseases
* Mental diseases
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Democritus University of Thrace
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Georgios Labiris
Professor (Associate) of Democritus University of Thrace
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Georgios Labiris, MD,PHD
Role: STUDY_CHAIR
Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Greece
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Ophthalmology, University Hospital of Alexandroupolis
Alexandroupoli, Evros, Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Labiris G, Panagiotopoulou EK, Chatzimichael E, Tzinava M, Mataftsi A, Delibasis K. Introduction of a digital near-vision reading test for normal and low vision adults: development and validation. Eye Vis (Lond). 2020 Oct 22;7:51. doi: 10.1186/s40662-020-00216-0. eCollection 2020.
Labiris G, Panagiotopoulou EK, Perente A, Ntonti P, Delibasis K, Fotiadis I, Konstantinidis A, Dardabounis D. Premium Monovision versus Bilateral Myopic Monovision, Hybrid Monovision and Bilateral Trifocal Implantation: A Comparative Study. Clin Ophthalmol. 2022 Mar 4;16:619-629. doi: 10.2147/OPTH.S351091. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ES13/Th9/22-10-2020
Identifier Type: -
Identifier Source: org_study_id